All In Biotech

Drug Trial Radar · NCT01911494

Community Level Interventions for Pre-eclampsia

The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 87,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

87,500

Planned (sponsor's estimate)

Start

Sep 2013

Primary completion

May 2018

Study completion Jun 2018

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Olabisi Onabanjo University; Centro de Investigacao em Saude de Manhica; Aga Khan University; Jawaharlal Nehru Medical College
First posted
Jul 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
Female only, from 15 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This project is being undertaken to test the hypothesis that implementing a community based package of care for women with hypertensive disorders of pregnancy will result in overall improvement in maternal and neonatal outcomes. This is based on the premise that there are three main modifiable reasons why women (and their fetuses/newborns) die due to pregnancy complications: 1) delays by the woman herself in recognizing the seriousness of her condition; 2) delays in her being assessed and then transported to a center capable of providing effective and life-saving interventions; and 3) delays in the health facility in providing those interventions. The treatments for pre-eclampsia that are poorly accessed in LMIC are 1) magnesium sulfate (MgSO4) for prevention and treatment of the grand mal seizures of eclampsia; 2) oral antihypertensive medication to lower maternal BP to reduce the risk of stroke. The CLIP pilot and definitive cRCT will investigate whether the community level intervention including implementation of the CLIP package (oral antihypertensive therapy when indicated, intramuscular (i.m.) MgSO4 when indicated; and appropriate referral to an CEmOC facility when indicated) of care will reduce the incidence of all-cause maternal morbidity and mortality.

Conditions

  • Pre-eclampsia
  • Hypertension, Pregnancy Induced

Interventions

  • Community EngagementBehavioral

    The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,

  • PIERS on the Move mHealth decision aidDevice

    This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.

  • Magnesium SulfateDrug

    Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.

  • MethyldopaDrug

    Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maternal or Perinatal death or morbidityTime frame: within 42 days of pregnancy

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Jawaharlal Nehru Medical College, Karnataka Lingayat Education University

    Belagavi, Karnataka, India

  • Centro de Investigacaoem Saude de Manhica (CISM)

    Maputo, Mozambique

  • Centre for Research in Reproductive Health, Olabisi Onabanjo University

    Sagamu, Ogun State, Nigeria

  • Aga Khan University

    Karachi, Sindh, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.